To investigate whether AKR1C3-mediated LDs accumulation potentiates the vulnerability of sorafenib-resistant HCC cells, we examined the effect of the combined treatment of sorafenib with FLU on tumor growth in a xenograft model. This evidence concerns the gene AKR1C3 and hepatocellular carcinoma.